Eli Lilly said on Wednesday the U.S. health regulator has approved its drug to treat adults with moderate-to-severe Crohn's ...

Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.

Eli Lilly shares dropped after the drugmaker cut its 2024 revenue guidance, citing lower-than-expected demand for its obesity ...

All told, Lilly stock still gained 33% in 2024, outperforming the S&P 500 and Nasdaq Composite. Unfortunately, Lilly ...

Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street ...

Eli Lilly and Merck & Co. are partnering with Purdue University to launch the Young Institute Pharmaceutical Manufacturing ...

Eli Lilly unexpectedly lowered its full-year 2024 guidance. The miss appears to stem from a lack of the typical December ...

Eli Lilly (NYSE: LLY) began a roll in late 2020 that lasted almost four years. During that time, it became the world's ...

In the first half of 2024, it seemed Eli Lilly (NYSE: LLY) could do no wrong. Is Eli Lilly a good stock to buy on the dip? On Jan. 14, CEO David Ricks told investors that 2024 sales would come in at ...

Eli Lilly agreed to acquire Scorpion Therapeutics’ breast cancer treatment program for up to $2.5 billion in cash.

Turning to 2025 guidance, Lilly noted that new medicines and new uses of existing medicines, expansion of production, and ...

The clearance broadens use of Omvoh, which is part of a slate of new medicines Lilly is counting on to build on its success ...